ClinicalTrials.gg
CompletedNCT01228747Updated Apr 3, 2025Results posted

A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)

A Phase 3 interventional study of Levetiracetam and Placebo in Epilepsy and Generalized Tonic-Clonic Seizures, sponsored by UCB Japan Co. Ltd.. Completed at 58 sites in 2 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by UCB Japan Co. Ltd. (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
361
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.

Enrollment
8th of 60
361 · median 94
Started
2010
with 3 others
Phase 3
28 of 60
2 open now
Registered
36th of 60
by date
Lead sponsor
7 of 60
UCB Japan Co. Ltd.

Among the 60 studies testing levetiracetam in Epilepsy, this one is the 8th largest by enrollment, is one of 4 that started in 2010, is one of 28 in phase 3, and was the 36th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing levetiracetam in Epilepsy, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of levetiracetam treatment used as adjunctive therapy in Japanese and Chinese epilepsy patients aged ≥16 years and with uncontrolled Generalized Tonic-Clonic seizures despite treatment with 1 or 2 anti-epileptic drugs.

03

Conditions studied

  • Epilepsy
  • Generalized Tonic-Clonic Seizures

Keywords

  • Levetiracetam
  • epilepsy
  • generalized tonic-clonic
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An epilepsy patient with generalized tonic-clonic seizures that are classifiable according to the ILAE classification of epileptic seizures (Epilepsia, 1981)
  • A patient on a stable dose of 1 or 2 anti-epileptic drugs for the last 4 weeks (potassium bromide and sodium bromide for the last 12 weeks) prior to and during the combined baseline period

Exclusion criteria

Exclusion Criteria:

  • Presence of any sign (clinical or imaging procedures) suggesting a progressive brain lesion/disease, in particular, progressive disorder with epileptic seizures
  • Diagnosis of Lennox-Gastaut Syndrome
  • Confirmed focal epilepsy based on clinical signs (seizure types), with consistent electroencephalogram and magnetic resonance imagining features
  • A history of convulsive or non-convulsive status epilepticus while taking concomitant anti-epileptic drugs for the last 3 months prior to Visit 1
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
361 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching placebo for 28 weeks

    Drug: Placebo

  • Experimental
    Levetiracetam

    Levetiracetam treatment with flexible dosing of 1000 mg/day or 2000 mg/day or 3000 mg/day for 28 weeks

    Drug: Levetiracetam

Interventions

  • Oral dose at flexible increase doses: 1000 mg/day or 2000 mg/day or 3000 mg/day, twice daily, 28 weeks

    Also known as: Keppra®

  • DrugPlacebo

    Matching oral placebo tablets twice daily for 28 weeks

06

What researchers measure

Primary outcomes

  1. Percentage Change From the Combined Baseline in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 28-week Treatment Period (Dose Adjustment + Evaluation Periods)

    Percentage change in generalized tonic-clonic (GTC) seizure frequency per week from Combined Baseline B over the Treatment Period A is calculated using the equation: Percentage change from Baseline = ((A-B)/B)\*100. Percentage change from baseline is not defined for subjects whose baseline information is missing / unknown or equal to zero, or whose seizure frequency per week is missing / unknown. A negative value in change in generalized tonic-clonic (GTC) seizure frequency indicates a reduction of generalized tonic-clonic (GTC) seizure frequency over the 28-week treatment Period. Combined Baseline means: a 4-week Retrospective Baseline + 4-week Prospective Baseline or 8-week Prospective Baseline

    Time frame: From Baseline to Week 28

Secondary outcomes

  1. The Percentage Change in Generalized Tonic-clonic Seizure Frequency Per Week From the Combined Baseline Over the Evaluation Period

    Percentage change in generalized tonic-clonic (GTC) seizure frequency per week from combined baseline B over the Evaluation Period A is calculated using the equation: Percentage change from Baseline = ((A-B)/B)\*100. Percentage change from baseline is not defined for subjects whose baseline Information is missing / unknown or equal to zero, or whose seizure frequency per week is missing / unknown. A negative value in change in generalized tonic-clonic (GTC) seizure frequency indicates a reduction of generalized tonic-clonic (GTC) seizure frequency. Combined Baseline means: a 4-week Retrospective Baseline + 4-week Prospective Baseline or 8-week Prospective Baseline.

    Time frame: From Baseline to Evaluation Period (Week 12 to Week 28)

  2. Generalized Tonic-clonic Seizures 50 % Responder Rate (the Proportion of Subjects With 50 % or More Reduction From the Combined Baseline in the Frequency of Generalized Tonic-clonic Seizures) During the Treatment Period

    A subject with an at least 50 % reduction in weekly generalized tonic-clonic (GTC) seizure frequency from Combined Baseline Period to the Treatment Period is considered a GTC 50 % responder. Combined Baseline means: a 4-week Retrospective Baseline + 4-week Prospective Baseline or 8-week Prospective Baseline

    Time frame: From Baseline to Week 28

  3. Generalized Tonic-clonic Seizures 50 % Responder Rate (the Proportion of Subjects With 50 % or More Reduction From the Combined Baseline in the Frequency of Generalized Tonic-clonic Seizures) During the Evaluation Period

    A subject with an at least 50 % reduction in weekly generalized tonic-clonic (GTC) seizure frequency from Combined Baseline Period to the Evaluation Period is considered a GTC 50 % responder. Combined Baseline means: a 4-week Retrospective Baseline + 4-week Prospective Baseline or 8-week Prospective Baseline

    Time frame: From Baseline to Evaluation Period (Week 12 to Week 28)

  4. Generalized Tonic-clonic Seizure Freedom Over the Evaluation Period

    A subject with a non-missing weekly generalized tonic-clonic (GTC) baseline seizure frequency and a weekly GTC seizure frequency of zero throughout the Evaluation Period, is considered as a GTC seizure-free subject on the Evaluation Period.

    Time frame: Evaluation Period (Week 12 to Week 28)

07

Results

Posted May 13, 2015

Participant flow

This study started to enroll subjects in Japan and China in October 2010.

Participant flow — Overall Study
MilestonePlaceboLevetiracetam
Started125126
Completed6081
Not completed6545
Withdrew: Adverse event84
Withdrew: Lack of efficacy4027
Withdrew: Protocol violation65
Withdrew: Lost to follow-up43
Withdrew: Withdrawal by subject51
Withdrew: Other reason25

Outcome measures

PrimaryPercentage Change From the Combined Baseline in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 28-week Treatment Period (Dose Adjustment + Evaluation Periods)

Percentage change in generalized tonic-clonic (GTC) seizure frequency per week from Combined Baseline B over the Treatment Period A is calculated using the equation: Percentage change from Baseline = ((A-B)/B)\*100. Percentage change from baseline is not defined for subjects whose baseline information is missing / unknown or equal to zero, or whose seizure frequency per week is missing / unknown. A negative value in change in generalized tonic-clonic (GTC) seizure frequency indicates a reduction of generalized tonic-clonic (GTC) seizure frequency over the 28-week treatment Period. Combined Baseline means: a 4-week Retrospective Baseline + 4-week Prospective Baseline or 8-week Prospective Baseline

Time frame:
From Baseline to Week 28
Reported as:
Mean · Percentage Change
Percentage Change From the Combined Baseline in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 28-week Treatment Period (Dose Adjustment + Evaluation Periods)
Percentage ChangePlaceboLevetiracetam
Percentage Change From the Combined Baseline in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 28-week Treatment Period (Dose Adjustment + Evaluation Periods)-13.19 ± 55.54-68.22 ± 34.95
Statistical analysis
  • Placebo vs Levetiracetam · ANCOVA · p = <0.0001 (Statistical testing was 2-sided, and was performed using a significance (α) level of 0.05.) · Mean difference (net): -56.13 · 95% CI -68.24 to -44.02
SecondaryThe Percentage Change in Generalized Tonic-clonic Seizure Frequency Per Week From the Combined Baseline Over the Evaluation Period

Percentage change in generalized tonic-clonic (GTC) seizure frequency per week from combined baseline B over the Evaluation Period A is calculated using the equation: Percentage change from Baseline = ((A-B)/B)\*100. Percentage change from baseline is not defined for subjects whose baseline Information is missing / unknown or equal to zero, or whose seizure frequency per week is missing / unknown. A negative value in change in generalized tonic-clonic (GTC) seizure frequency indicates a reduction of generalized tonic-clonic (GTC) seizure frequency. Combined Baseline means: a 4-week Retrospective Baseline + 4-week Prospective Baseline or 8-week Prospective Baseline.

Time frame:
From Baseline to Evaluation Period (Week 12 to Week 28)
Reported as:
Mean · Percentage Change
The Percentage Change in Generalized Tonic-clonic Seizure Frequency Per Week From the Combined Baseline Over the Evaluation Period
Percentage ChangePlaceboLevetiracetam
The Percentage Change in Generalized Tonic-clonic Seizure Frequency Per Week From the Combined Baseline Over the Evaluation Period-4.44 ± 153.82-68.27 ± 42.63
SecondaryGeneralized Tonic-clonic Seizures 50 % Responder Rate (the Proportion of Subjects With 50 % or More Reduction From the Combined Baseline in the Frequency of Generalized Tonic-clonic Seizures) During the Treatment Period

A subject with an at least 50 % reduction in weekly generalized tonic-clonic (GTC) seizure frequency from Combined Baseline Period to the Treatment Period is considered a GTC 50 % responder. Combined Baseline means: a 4-week Retrospective Baseline + 4-week Prospective Baseline or 8-week Prospective Baseline

Time frame:
From Baseline to Week 28
Reported as:
Number · participants
Generalized Tonic-clonic Seizures 50 % Responder Rate (the Proportion of Subjects With 50 % or More Reduction From the Combined Baseline in the Frequency of Generalized Tonic-clonic Seizures) During the Treatment Period
participantsPlaceboLevetiracetam
Generalized Tonic-clonic Seizures 50 % Responder Rate (the Proportion of Subjects With 50 % or More Reduction From the Combined Baseline in the Frequency of Generalized Tonic-clonic Seizures) During the Treatment Period3191
SecondaryGeneralized Tonic-clonic Seizures 50 % Responder Rate (the Proportion of Subjects With 50 % or More Reduction From the Combined Baseline in the Frequency of Generalized Tonic-clonic Seizures) During the Evaluation Period

A subject with an at least 50 % reduction in weekly generalized tonic-clonic (GTC) seizure frequency from Combined Baseline Period to the Evaluation Period is considered a GTC 50 % responder. Combined Baseline means: a 4-week Retrospective Baseline + 4-week Prospective Baseline or 8-week Prospective Baseline

Time frame:
From Baseline to Evaluation Period (Week 12 to Week 28)
Reported as:
Number · participants
Generalized Tonic-clonic Seizures 50 % Responder Rate (the Proportion of Subjects With 50 % or More Reduction From the Combined Baseline in the Frequency of Generalized Tonic-clonic Seizures) During the Evaluation Period
participantsPlaceboLevetiracetam
Generalized Tonic-clonic Seizures 50 % Responder Rate (the Proportion of Subjects With 50 % or More Reduction From the Combined Baseline in the Frequency of Generalized Tonic-clonic Seizures) During the Evaluation Period3382
SecondaryGeneralized Tonic-clonic Seizure Freedom Over the Evaluation Period

A subject with a non-missing weekly generalized tonic-clonic (GTC) baseline seizure frequency and a weekly GTC seizure frequency of zero throughout the Evaluation Period, is considered as a GTC seizure-free subject on the Evaluation Period.

Time frame:
Evaluation Period (Week 12 to Week 28)
Reported as:
Number · participants
Generalized Tonic-clonic Seizure Freedom Over the Evaluation Period
participantsPlaceboLevetiracetam
Generalized Tonic-clonic Seizure Freedom Over the Evaluation Period332

Adverse events

Collected over Adverse Events were collected from the Prospective Baseline Period ( Week -8 to Week 0) over Dose Adjustment (12 weeks) and Evaluation Period (16 weeks) until Conversion or Withdrawal Period (4-6 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—4/125 (3.2%)32/125 (25.6%)
Levetiracetam—1/126 (0.8%)40/126 (31.7%)
Most frequent serious events
Most frequent serious events
EventPlaceboLevetiracetam
DrowningGeneral disorders2/1250/126
Sudden unexplained death in epilepsyGeneral disorders1/1250/126
EpilepsyNervous system disorders1/1250/126
PneumoniaInfections and infestations0/1251/126
Most frequent other events
Most frequent other events
EventPlaceboLevetiracetam
NasopharyngitisInfections and infestations20/12524/126
Protein urine presentInvestigations1/12510/126
DizzinessNervous system disorders9/1254/126
PyrexiaGeneral disorders5/1257/126
Platelet count decreasedInvestigations4/1257/126

Baseline characteristics

Baseline Characteristics refer to the Safety Set (SS), which is a subset of the Randomized Set and consisted of all subjects who received at least 1 dose of study medication after randomization, either Placebo or Levetiracetam.

Age, Categorical
Age, Categorical(Participants)PlaceboLevetiracetamTotal
<=18 years111021
Between 18 and 65 years113115228
>=65 years112
Age, Continuous
Age, Continuous(years)PlaceboLevetiracetamTotal
Mean32.8 ± 12.531.5 ± 11.332.2 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLevetiracetamTotal
Female494796
Male7679155
Region of Enrollment
Region of Enrollment(participants)PlaceboLevetiracetamTotal
China104104208
Japan212243
08

Study locations

58 sites
  • 1
    Beijing, China
  • 9
    Beijing, China
  • 12
    Changchun, China
  • 19
    Chengdu, China
  • 6
    Chengdu, China
  • 10
    Chongqing, China
  • 16
    Guangzhou, China
  • 5
    Guangzhou, China
  • 18
    Harbin, China
  • 13
    Kunming, China
  • 22
    Nanjing, China
  • 14
    Qingdao, China
  • 2
    Shanghai, China
  • 3
    Shanghai, China
  • 17
    Shenyang, China
  • 15
    Taiyuan, China
  • 8
    Wuhan, China
  • 7
    Xi'an, China
  • 20
    Xian, China
  • 152
    Fujisawa, Japan
  • 112
    Fukuoka, Japan
  • 113
    Fukuoka, Japan
  • 166
    Fukuoka, Japan
  • 187
    Fukushima, Japan
  • 124
    Hamamatsu, Japan
  • 175
    Higashiosaka, Japan
  • 162
    Himeji, Japan
  • 110
    Hiroshima, Japan
  • 177
    Hiroshima, Japan
  • 165
    Iizuka, Japan
  • 143
    Kagoshima, Japan
  • 156
    Kagoshima, Japan
  • 176
    Kameda, Japan
  • 150
    Kashihara, Japan
  • 153
    Kashiwakazi, Japan
  • 105
    Kokubunji, Japan
  • 172
    Miyakonojo, Japan
  • 179
    Miyazaki, Japan
  • 186
    Miyazaki, Japan
  • 189
    Nagoya, Japan
  • 106
    Niigata, Japan
  • 158
    Okayama, Japan
  • 129
    Osaka-sayama, Japan
  • 157
    Osaka, Japan
  • 174
    Osaka, Japan
  • 130
    Otaru, Japan
  • 170
    Saito, Japan
  • 147
    Sakai, Japan
  • 194
    Sakai, Japan
  • 117
    Sapporo, Japan
  • 131
    Sapporo, Japan
  • 304
    Sapporo, Japan
  • 103
    Sendai, Japan
  • 168
    Shimajiri, Japan
  • 138
    Shimotsuke, Japan
  • 121
    Shizuoka, Japan
  • 120
    Tokyo, Japan
  • 111
    Ube, Japan
09

References and documents

Publications

  • Wu L, Yagi K, Hong Z, Liao W, Wang X, Zhou D, Inoue Y, Ohtsuka Y, Sasagawa M, Terada K, Du X, Muramoto Y, Sano T. Adjunctive levetiracetam in the treatment of Chinese and Japanese adults with generalized tonic-clonic seizures: A double-blind, randomized, placebo-controlled trial. Epilepsia Open. 2018 Sep 29;3(4):474-484. doi: 10.1002/epi4.12255. eCollection 2018 Dec. PubMed 30525116 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Apr 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in May 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2010
First posted
Oct 26, 2010
Start
Oct 2010
Primary completionActual
Apr 2014
CompletionActual
May 2014
Results first posted
May 13, 2015
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01228747
Lead sponsor
UCB Japan Co. Ltd.
Responsible party
Sponsor
First posted
Oct 26, 2010
Start date
Oct 2010
Primary completion
Apr 2014
Completion
May 2014
Results posted
May 13, 2015
Last update
Apr 3, 2025

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion